JAK Inhibitors for Vitiligo

The presentation discusses the use of JAK inhibitors in treating vitiligo, focusing on their mechanisms, efficacy, and future research directions. The speaker highlights the rationale behind using JAK inhibitors, particularly highlighting the JAK1 and JAK2 pathways' relevance to the management of vitiligo. They mention the clinical experiences leading to the development of topical ruxolitinib, which gained approval after a significant phase three study demonstrated its effectiveness in improving facial vitiligo. The importance of measuring not just facial, but total body repigmentation is emphasized, as many patients experience lesions in various areas. While topical treatments show promise, ongoing studies explore systemic JAK inhibitors like ruxolitinib, povicitinib, and ubadacitinib. The speaker notes that while these medications have shown efficacy, concerns remain regarding their safety and the challenge of maintaining pigmentation post-treatment. Notably, combining JAK inhibitors with narrowband UVB phototherapy has shown enhanced results. Future clinical trials are anticipated to further assess the effectiveness of JAK inhibitors, particularly in achieving satisfactory repigmentation in challenging areas such as the hands. The importance of addressing both inflammation and stimulating melanocyte activity in vitiligo treatment is emphasized, underscoring the need for innovative dual therapies in future studies.